[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial

Giulia Polverari
AFFIDEA

Francesco Ceci
Universita degli Studi di Torino Scuola di Medicina

Roberto Passera
Universita degli Studi di Torino Scuola di Medicina

Jacquelyn Crane
University of California Los Angeles

Lin Du
University of California Los Angeles

Gang Li
University of California Los Angeles

Stefano Fanti
Universita di Bologna

Nicholas Bernthal
University of California Los Angeles

Fritz C Eilber
University of California Los Angeles

Martin Allen-Auerbach
University of California Los Angeles

Johannes Czemin
University of California Los Angeles

Jeremie Calais (✉ jcalais@mednet.ucla.edu)
University of California Los Angeles  https://orcid.org/0000-0002-8839-4379

Noah Federman
University of California Los Angeles

Original research

Keywords: [18F]FDG; PET/CT, sarcoma, neoadjuvant chemotherapy, therapy response, pediatrics
Abstract

**Introduction:** This is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate $^{18}$F-FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX).

**Methods:** Bone or soft tissue sarcoma patients with i) baseline $^{18}$F-FDG PET/CT within four weeks prior to the start of neo-CTX (PET1), ii) early interim $^{18}$F-FDG PET/CT (six weeks after the start of neo-CTX (PET2), iii) evaluation of neo-CTX response by histology or MRI, and iv) definitive therapy after neo-CTX (surgery or radiation) were included. Semi-quantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 ($\Delta$PET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and $\Delta$PET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if $^{18}$F-FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a sub-population of patients with bone involvement only.

**Results:** Thirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had Osteosarcoma, 13/34 (38%) Ewing Sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP ($p <0.02$). $\Delta$MTV was associated with tissue response to neo-CTX ($p=0.047$). None of the PET1, PET2 or $\Delta$PET parameters were associated with OS.

**Conclusion:** $^{18}$F-FDG PET/CT performed six weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma.

Introduction

Bone and soft tissue sarcomas are the most common primary bone malignancies in children. Their incidence ranges from 0.2 to 0.3/100,000/year (1, 2). Depending on the histologic sarcoma subtype patient management may include neo-adjuvant chemotherapy (neo-CTX) and radical surgery with or without radiation therapy (RT) followed by adjuvant CTX. For soft tissue sarcomas, the therapeutic strategy is based on a risk classification that considers TNM stage, histologic subtype, and primary tumor location. Local recurrence or distant metastases occur in up to 40% of patients who initially receive treatment with curative intent (3). The 5-year survival rate in patients with metastases is 20% compared to 65% for patients with localized disease (4). Clinical characteristics such as tumor grade, size, presence of distant metastases or skip lesions, surgical margin status and histologic response to neo-CTX have been reported to be predictors of survival in bone and soft tissue sarcomas (5,6,7). However, these
prognostic factors are not highly accurate. Histologic response is determined by examination of resected specimens after the completion of neo-CTX. A non-invasive early interim biomarker that could permit reliable response predictions would be useful to guide changes in treatment of non-responding patients (8).

\[^{18}\text{F}]\text{FDG PET/CT}\] is used to accurately stage and assess treatment response in almost all cancers, including those in pediatric patients (9-12). However, for pediatric bone and soft tissue sarcoma the role of \[^{18}\text{F}]\text{FDG PET/CT}\] is not clearly defined. In this prospective study we assessed the value of semi-quantitative \[^{18}\text{F}]\text{FDG PET/CT}\] parameters as a potential early intermediate biomarker for response to neo-CTX in pediatric patients with high-grade bone and soft tissue sarcomas.

**Methods**

**Objectives**

The primary aim of this prospective study was to evaluate whether semi-quantitative \[^{18}\text{F}]\text{FDG PET/CT}\] parameters acquired at baseline (PET1) and during therapy (PET2) are predictive of time to progression (TTP) and overall survival (OS) in children with high-grade bone or soft tissue sarcomas.

The secondary objective was to determine whether \[^{18}\text{F}]\text{FDG PET/CT}\] was able to predict the response to neo-CTX defined by percent tumor necrosis in the resected tumor or by MRI performed after the completion of neo-CTX. Primary and secondary aims were also evaluated in the sub-population of patients with bone sarcomas.

**Study design and participants**

This was a prospective, open-label, observational, single-arm, single-center study approved by the local ethics committee (UCLA-IRB#10-000246) in pediatric patients with high-grade bone or soft tissue sarcomas. All patients with histologically or cytologically confirmed bone or soft tissue sarcoma who were evaluated for management of disease prior to neo-CTX before definitive therapy (surgery, radiation therapy (RT)) were eligible. Written informed consent was obtained from all participants or guardians at enrollment along with signed participant assent, when applicable.

Enrolled patients underwent \[^{18}\text{F}]\text{FDG PET/CT}\] at 2 time points: within 4 weeks before the start of neo-CTX (baseline, PET1) and at 6 weeks after the start of CTX (early interim, PET2).

\[^{18}\text{F}]\text{FDG PET/CT}\] findings were confirmed by pathology when available or by follow-up \[^{18}\text{F}]\text{FDG PET/CT}\] and/or standard clinical follow-up.

Excised tumors were examined for extent of necrosis and \(\geq 90\%\) necrosis (<10% viable tumor cells) was considered a complete histopathological response to neo-CTX (13). In patients undergoing definitive RT, response was assessed by MRI at the end of neo-CTX (14,15). Patients with a complete disappearance of
the soft tissue component of the tumor on MRI were considered responders. Pathology and MRI clinical reports were used to obtain the pathological response.

$[^{18}F]$FDG PET/CT Image Acquisition

Patients were instructed to fast for at least 6 hours before the scan, and blood glucose levels were measured before injection of $[^{18}F]$FDG. All patients had serum glucose levels of <150 mg/dl prior to the scan. None of the patients had a history of diabetes.

$[^{18}F]$FDG was administered by intravenous injection at the activity of 0.1 mCi/Kg and up to a total maximum of 10 mCi. After 60-minute of uptake time, images were acquired using a 64-detector PET/CT scanner (2007 Biograph 64 Truepoint or 2010 Biograph mCT 64; Siemens). A low-dose CT for attenuation correction (132 kVp, 35 mAs (CareDose protocol), 0.5s tube rotation, 5-mm slice collimation, bed speed 8 mm/s) was performed after administration of intravenous contrast (115 mL of iohexol [Omnipaque 350; GE Healthcare]) unless contraindicated. CT images were acquired along the same length of the patient’s body as the PET (Full-body PET/CT, from vertex to toes). The time per bed position was 2 min. Iterative methods were used to reconstruct the PET images with a slice thickness of 2 mm. All PET images were reconstructed using attenuation, dead-time, random-event and scatter corrections. PET images were reconstructed with an iterative algorithm (ordered-subset expectation maximization) in a 200 x 200 matrix (3-dimensional, 2 iterations, 24 subsets, Gaussian filter 5.0).

Visual Analysis

PET/CT images were retrospectively analyzed on an OsiriX workstation by two UCLA investigators (GP, FC), with more than 5 years of experience in reading oncologic PET images. The readers had access to all patient medical information. Images were interpreted by consensus. Any focal non-physiologic $[^{18}F]$FDG uptake above surrounding background activity was considered consistent with malignancy. Metastatic sites were classified as regional lymph nodes (LNs), lung, or other distant metastases (other skeletal segments and/or other distant sites).

Semi-quantitative Analysis

Standardized Uptake Value (SUV) was defined as activity concentration (Bq/mL) divided by injected activity (Bq) normalized to body weight. The highest voxel value (SUVmax) was obtained in a volume of interest (VOI) covering the entire tumor as defined by the investigator (GP). SUVpeak and SUVmean were also calculated within the same VOI. The Metabolic Tumor Volume (MTV) was determined with a threshold of 40% of the SUVmax. When normal tissues with high $[^{18}F]$FDG uptake were included in the VOIs or the VOIs excluded obvious tumor tissue, manual adjustment was applied. Total Lesion Glycolysis (TLG) was defined as the product of SUVmean and MTV. Reduction in SUV parameters were defined as $\Delta$SUV= [(SUV2 − SUV1)/SUV1]. Change in MTV and TLG were calculated as follow: $\Delta$MTV= [(MTV2 − MTV1)/MTV1]; $\Delta$TLG= [(TLG2 − TLG1)/TLG1].
Finally, response to neo-CTX was evaluated applying PET EORTC criteria (16).

Statistical Analysis

Median and interquartile range (IQR) were used as descriptive statistics for continuous variables, while absolute and relative frequencies for categorical ones. For time-to-event data, the endpoints were: OS defined as the time interval from the start of neo-CTX to the date of last follow-up or the date of death from any cause. TTP was defined as the time interval from the start of neo-CTX to the date of the first event or the date of last follow-up for patients who had no events (recurrent or progressive disease and death from any cause).

A univariate Cox proportional hazards regression model was used to assess the association between TTP, OS and the following covariates of interest: PET1-SUVmax, PET1-SUVmean, PET1-SUVpeak, PET1-MTV, PET1-TLG, PET2-SUVmax, PET2-SUVmean, PET2-SUVpeak, PET2-MTV, PET2-TLG and changes therein. Changes between PET1 and PET2 parameters (ΔPET parameters) were expressed in percentage of reduction. Kaplan Meier curves and log-rank test were used to summarize and compare the survival experience between PET1, PET2 and ΔPET parameters on cut-off values (median, upper quantile and lower quantile). Mann-Whitney test was used to test the association between PET1, PET2 and ΔPET parameters to the neo-CTX response status (yes/no). Data were analyzed by R 3.6.1 (R Foundation for Statistical Computing, Vienna-A, http://www.R-project.org).

Results

Population Characteristics

The study flowchart is provided in Figure 1 and patients characteristics listed in Table 1. Thirty-four consecutive patients (10 females and 24 males; median age of 15.1 years; 7.4-19.7 years) were enrolled from July 2010 to November 2016: 17/34 (50%) had Osteosarcoma, 13/34 (38%) had Ewing Sarcoma (4/13 (31%) soft tissue and 9/13 (69%) bone), 2/34 (6%) had synovial sarcoma and 2/34 (6%) had embryonal sarcoma of the liver. According to the revised American Joint Committee on Cancer staging system (AJCC) (15), 16/34 (47%) patients were classified as stage IIb, 11/34 (32%) as stage IIa and 7/34 (21%) had skip or distant metastasis at diagnosis (stage III, IV; 1 skip lesion, 1 distant bone metastasis and 5 lung metastases).

Therapy protocols

All 17 patients with osteosarcoma were treated according to the Children's Oncology Group (COG) Protocol with 10 weeks of neo-CTX (high-dose methotrexate, doxorubicin and cisplatin) before surgery (16 resections with reconstruction/replacement, 1 amputation) followed by 18 weeks of adjuvant-CTX (high-dose methotrexate, doxorubicin and cisplatin) for low-risk patients or 29 weeks of adjuvant-CTX with addition of ifosfamide and etoposide in high-risk patients (17,18). Ewing sarcoma patients (n=13) were treated as per COG AEWS1031 protocol composed by an initial 12 week course of interval
compression CTX (Vincristine, Doxorubicin, Cytoxan, alternating with Ifosfamide and Etoposide) followed either by surgical removal of the tumor (8/13 (62%) or definitive RT (5/13 (38%)). Following definitive therapy, CTX was continued for approximately 6 months (consolidation). Patients with synovial sarcoma (n=2) and embryonal sarcoma of the liver (n=2) were treated with doxorubicin and ifosfamide according to COG ARST0332 combined with surgery and radiation (19). The treatment schemas for patients with osteosarcoma, synovial sarcoma, and embryonal sarcoma of the liver are shown in Figure 2. The treatment schema for patients with Ewing Sarcoma is not included as the data from that study is not yet published.

Follow-up and therapy response assessment

Median follow-up was 39 months (range 16-84). 8/34 patients (24%) died from cancer-related causes while 9/34 (27%) were alive with disease and 17/34 (50%) had no evidence of residual/recurrent disease at the last follow-up. The median time between primary therapy and the disease relapse was 14.4 months (4.2 – 53.4 months) and the median time between primary therapy and cancer-related death was 33.6 (19.7 – 73.5 months). The median OS was 71 months while the median TTP was 33.5 months. The shortest follow-up in patient who did not show disease progression was 16 months. In 7/34 patients with metastatic disease (21%) the median OS and TTP was 35 and 13.2 months, respectively (3/7 died (43%), 4/7 were alive with disease (57%) at last follow-up).

Tumor tissue response to neo-CTX was evaluated in all patients (necrosis> 90% at histopathology of excised tumors in 29 and by MRI in 5 patients). Fifteen of 34 patients (44.1%) were classified as responders (15/15 by histopathology evaluation) while 19/34 patients (55.9%) were considered non-responders (14/34 by histopathology and 5/34 by MRI evaluation). The average percentage of CTX induced tumor necrosis was 68%, ranging from 5% to 99%. Six deaths were reported among the non-responders (n=14, median OS=72 months), while no events were observed in the responders group (n=15, median OS=not reached).

[^18]F FDG PET/CT findings

Primary tumors were identified on [^18]F FDG PET/CT in all patients. Twenty-seven /34 patients (79%) had localized disease while 7/34 patients (21%) had metastatic disease (Figure 3). These included 2 patients with Ewing sarcoma (left femur with left iliac bone metastasis; 1 patient with Ewing sarcoma of the chest wall (11th rib) with vertebral body metastasis). Five patients (3 osteosarcomas, 1 synovial and 1 liver embryonal sarcoma) showed sub-centimeter bilateral lung nodules with faint [^18]F FDG uptake. All metastatic lesions seen at PET1 showed partial or complete metabolic response at PET2. No new metastatic lesion at PET2 was observed.

All primary tumors had increased [^18]F FDG uptake. Baseline SUVmax, SUVmean, SUVpeak, MTV and TLG median values were 7.9 (5.3-10.6 IQR), 3.8 (3.0-4.9 IQR), 6.0 (4.0-7.4 IQR), 161.0 (85.2-262.4 IQR) and 104.7 (54.8-259.9 IQR), respectively. In PET2 the same parameters decreased to 3.1 (2.2-4.0 IQR), 2.0 (1.4-
2.7 IQR), 2.4 (1.8-3.4 IQR), 72.0 (34.8-131.8 IQR) and 45.4 (19.4-105.5 IQR), respectively. PET1, PET2-parameters and their changes are listed in Table 2. Figure 4 and figure 5 show two examples of patients responding and non-responding to neo-CTX, respectively.

[^18F]FDG PET parameters for prediction of survival

None of PET1-parameters or the ΔPET were significantly associated with TTP in the univariate Cox regression model (Table 3). All PET2-parameters were significantly associated with TTP (Table 3, p<0.02): patients with higher SUVmax, SUVmean, SUVpeak, MTV and TLG on PET2 had earlier disease progression than those patients presenting with lower values. TTP was shorter in patients with PET2-SUVmax >3.1 (median PET2-SUVmax) (Figure 6, p=0.016) and with PET2-SUVpeak >2.4 (median value) (p=0.02), PET2-SUVmean >1.9 (median value) (p=0.007), PET2-MTV >131.8 (upper quartile value) (p=0.01) and PET2-TLG >105.5 (upper quartile) (p=0.002). All these data are summarized in Supplemental Figure 1. An association was observed for ΔSUVmean (p=0.017), ΔMTV (p=0.028) and ΔTLG (p=0.031) with the relapse status at last follow-up (Supplemental Table 1). None of the PET1, PET2 and ΔPET parameters were associated with OS (Supplemental Table 2). Due to the low number of events (8/34 patients died while 17/34 had a recurrent/progressive disease), multivariate Cox analysis was not performed. Finally, response to neo-CTX has been evaluated using PET parameters, applying EORTC criteria (18). One patient was considered as complete responder according to PET EORTC criteria, 23/34 as partial responder, 4/34 as stable disease and 3/34 as progressive disease. No statistically significant association has been observed between PET EORTC response to therapy criteria and TTP (p=0.59) or OS (p=0.94).

[^18F]FDG PET parameters for prediction of pathological response

No significant association between PET1 and PET2-parameters and the response to neo-CTX was observed (Table 4). Despite lack of statistical significance, the response rate was higher in patients with PET2-SUVmax <3.1 (median value) (60% vs 21%; p>0.05). An association between ΔMTV (p=0.037) and response to neo-CTX was observed while other ΔPET parameters did not show significant associations (Table 4). No statistically significant associations have been observed between PET EORTC response to therapy criteria and the pathological response to neo-CTX. These results are summarized in Supplemental Table 3.

**Bone Sarcoma Only Sub-population**

Considering the presence of multiple tumor types in our pediatric population, a post-hoc sub-analysis was performed in patients with bone sarcoma only (n=26; osteosarcoma=17; Ewing sarcoma=9). In this bone sarcoma sub-population, all PET2 parameters showed a statistically significant association with TTP, confirming the results also observed in the full study population (Supplemental Table 4).

**Discussion**
In this prospective single center study, a significant association between early interim $[^{18}\text{F}]$FDG PET2 parameters and TTP was observed. Patients with higher residual disease metabolic activity at 6 weeks after initiation of neo-CTX study had worse outcomes compared to those with no or only mild residual $[^{18}\text{F}]$FDG activity. Additionally, patients showing a lower MTV reduction from PET1 to PET2 had a lower pathological response rate. However, none of the PET parameters were predictive of OS.

$[^{18}\text{F}]$FDG PET/CT is important for staging and therapy response assessment of patients with high-grade bone and soft tissue sarcomas (10,20). However, limited data are currently available regarding the potential role of early interim PET/CT performed 6 weeks after neo-CTX initiation as a predictor of patient outcome, especially in the pediatric population. Conflicting published results are probably due to heterogeneous patient populations, different therapy regimen and different time points of PET/CT evaluations. Costelloe et al. reported in a mixed population of pediatric and adult bone sarcoma patients that SUVmax and TLG values measured before and after neo-CTX provided predictive information about treatment response (21). In a small study of bone sarcoma patients, changes in $[^{18}\text{F}]$FDG -SUVmax at the end of neo-CTX predicted histopathologic responders and non-responders (22). However, as both studies measured glucose metabolic parameters after completion of neo-CTX, the impact on managing these patients appears limited. In the present study glucose metabolism responses were measured early during neo-CTX. Earlier identification of non-responders to neo-CTX could lead to meaningful treatment changes. In the current study a significant association between the early interim $[^{18}\text{F}]$FDG PET parameters and patient outcome was observed. However, no significant association between the baseline $[^{18}\text{F}]$FDG PET parameters and TTP was observed. This contrasts with other studies reporting PET1-SUVmax as a prognostic biomarker (23,24).

None of PET1, PET2 and $\Delta$PET parameters were associated with OS. This is probably due to the relatively small sample size and the limited number of events in the current study population.

Histologic response to neo-CTX is known to be a prognostic indicator in bone and soft tissue sarcoma, especially in osteosarcoma. Patients with >90% tumor necrosis in response to treatment have improved outcomes (13). In contrast to other studies (24-27) we did not observe a significant association between any baseline or early interim $[^{18}\text{F}]$FDG PET parameters and the response to treatment assessed by the percentage of tumor necrosis (n=29) or by MRI evaluation (n=5). However, we observed a significant association of $\Delta$MTV with the pathological response to neo-CTX. Additionally, patients with higher PET2-SUVmax were less likely to be responders to neo-CTX although without statistical significance. These results suggest that tumor metabolic activity changes under neo-CTX as assessed on early interim $[^{18}\text{F}]$FDG PET2 can be integrated into the clinical risk prognostic assessment.

$[^{18}\text{F}]$FDG PET/CT is a whole-body imaging modality and can detect distant metastatic lesions. In our cohort patients with metastatic disease had worst outcome. Of note, all metastatic lesions showed partial or complete response on PET2. It is considered standard of care to treat distant metastases with local
control methods (surgery and/or radiation). Whether or not the prognosis is altered with this aggressive approach is controversial.

The main limitation of the study is its small sample size and the heterogeneity of the included sarcoma sub-types. However, each tumor sub-type was treated under the same therapy protocol. Results of the study were comparable in the sub-population of patients with bone sarcoma only (osteo- and Ewing sarcoma). Of note, patients with rhabdomyosarcoma were not included in this study as they were enrolled on competing COG therapeutic clinical trials, which included PET imaging as an experimental aim. Further sub-analyses considering the different tumor subtypes were not feasible considering the small sample size and the limited number of events. Larger and more homogeneous cohorts will be required to determine whether early interim $[^{18}\text{F}]$FDG PET/CT imaging can be useful for early treatment response predictions and prognostic information. However, such studies are difficult to conduct as bone and soft tissue sarcomas are rare neoplasms, especially when only considering pediatrics patients only. Another limitation is the lack of control for tumor necrosis. The data reported were obtained using the pathology and MRI clinical reports considered as reference in the treatment management of the patient. Finally, the comparison with the RECIST criteria for assessing the response to neo-CTX was not performed because of heterogeneous conventional imaging follow-up (modality, time points).

**Conclusion**

In this prospective single center study of 34 pediatric patients with sarcoma, the intensity of residual metabolic tumor activity on early interim $[^{18}\text{F}]$FDG PET/CT studies performed six weeks after the start of neo-CTX was associated with earlier TTP but not OS. Additionally, MTV reduction after neo-CTX was associated with tumor pathological response. $[^{18}\text{F}]$FDG PET/CT may serve as a useful early prognostic marker in pediatric patients with high-grade bone and soft tissue sarcoma.

**Declarations**

**Ethics approval and consent to participate**

Written informed consent was obtained from all participants or guardians at enrollment along with signed participant assent, when applicable.

This study was approved by the local ethics committee (UCLA-IRB#10-000246).

**Consent for publication:**

Consent to publish was obtain from all participants or guardians at enrollment along with signed participant assent, when applicable, as part of the informed consent form.
Availability of data and materials:

The datasets used during the current study are available from the corresponding author on reasonable request.

Competing interests

All authors declare no conflict of interest in relation with the present study.

Funding:

This study was self-funded (discretionary funds).
Noah Federman is supported by the NIH/NCATS Grant # UL1TR001881.

Authors Contributions:

Design of the study (GP, FC, JCz, JCa, NF); data collection (GP, FC); PET images reading (GP, FC); data analysis (GP, FC, RP, JCr, JCa); statistical analysis (RP, LD, GL); manuscript draft (GP, FC, JCr, NB, FE, MA, SF, JCz, JCa, NF); study supervision (FC, JCz, JCa, NF).

Acknowledgements

Not applicable

References

1. The EES Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2014;25(suppl_3):iii113-iii23.
2. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate. Journal of Clinical Oncology. 2005;23(9):2004-11.
3. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. Journal of Clinical Oncology. 2003;21(10):2011-8.
4. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. Journal of Clinical Oncology. 1992;10(1):5-15.
5. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. Journal of Clinical Oncology. 1994;12(2):423-31.
6. Waxweiler TV, Rusthoven CG, Proper MS, Cost CR, Cost NG, Donaldson N, et al. Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Children: A Surveillance, Epidemiology, and End
Results Analysis Validating COG Risk Stratifications. Int J Radiat Oncol Biol Phys. 2015 Jun 1. 92 (2):339-48.

7. Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2020 Jan;21(1):145-161.

8. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–1230

9. Herrmann K, Benz MR, Czernin J, et al. [18F]FDG PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012 Apr 1;18(7):2024-31.

10. Angelini A, Ceci F, Castellucci P, et al. The role of (18)F-[18F]FDG PET/CT in the detection of osteosarcoma recurrence. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1712-1720.

11. Kitajima K, Okada M, Yoshihara K, Tokugawa T, Sawada A, Yoshihara S, et al. Predictive value of interim [18F]FDG PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP. Oncotarget. 2019 Sep 10;10(52):5403-5411.

12. Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019 Sep 16.

13. Wardelmann E, Haas RL, Bovée JV, et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2016;53:84- doi:10.1016/j.ejca.2015.09.021

14. Messiou C, Bonvalot S, Gronchi A, et al. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. Eur J Cancer. 2016;56;37- doi:10.1016/j.ejca.2015.12.008.

15. Tanaka K, Ozaki T. New TNM classication (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol. 2018 Nov 13. doi: 10.1093/jjco/hyy157. [Epub ahead of print] PubMed PMID: 30423153.

16. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773–82.
17. Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial [published correction appears in J Clin Oncol. 2016 Nov 20;34(33):4059]. J Clin Oncol. 2015;33(20):2279-2287. doi:10.1200/JCO.2014.60.0734.

18. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396-1408. doi:10.1016/S1470-2045(16)30214-5.

19. Spunt SL, Million L, Chi YY, et al. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2020;21(1):145-161. doi:10.1016/S1470-2045(19)30672-2.

20. Harrison DJ, Parisi MT, Shulkin BL. The Role of $^{18}$F-$^{18}$FDG PET/CT in Pediatric Sarcoma. Semin Nucl Med. 2017;47(3):229–241.

21. Costelloe CM, Macapinlac HA, Madewell JE, et al. $^{18}$F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340–347

22. Caldarella C, Salsano M, Isgrò MA, Treglia G. The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma. Int J Mol Imaging. 2012;2012:870301.

23. Byun BH, Kong CB, Park J, et al. Initial metabolic tumor volume measured by $^{18}$F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities. J Nucl Med. 2013;54:1725–1732.

24. Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, et al. The role of $^{18}$F-FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):215-223.

25. Davis JC, Daw NC, Navid F, Billups CA, Wu J, Bahrami A, et al. $^{18}$F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma. Journal of Nuclear Medicine. 2018;59(1):25-30.

26. Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579–1584.

27. Kong CB, Byun BH, Lim I, et al. $^{18}$F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging. 2013;40:728–736.

Tables

Table 1: Study population characteristics.
| Characteristics          | Value                                      |
|-------------------------|--------------------------------------------|
| Age                     | Median 15.1 (7.4 – 19.7)                   |
| Sex                     |                                            |
| Male                    | 24/34 (70.6%)                              |
| Female                  | 10/34 (29.4%)                              |
| Histological Variant    |                                            |
| Osteosarcoma            | 17/34 (50%)                                |
| Ewing Sarcoma           | 13/34 (38.2%)                              |
| Synovial Sarcoma        | 2/34 (5.9%)                                |
| Liver Embryonal Sarcoma | 2/34 (5.9%)                                |
| Site                    |                                            |
| Extremities             | 22/34 (64.8%)                              |
| Scapula                 | 2/34 (5.9%)                                |
| Spine                   | 1/34 (2.9%)                                |
| Pelvis                  | 2/34 (5.9%)                                |
| Chest/abdominal         | 3/34 (8.8%)                                |
| Lung                    | 1/34 (2.9%)                                |
| Liver                   | 3/34 (8.8%)                                |
| AJCC                    |                                            |
| IIa                     | 11/34 (32.4%)                              |
| IIB                     | 16/34 (47.1%)                              |
| III                     | 1/34 (2.9%)                                |
| IV                      | 6/34 (17.6%)                               |
| Primary Therapy         |                                            |
| Radical Surgery         | 29/34 (85.3%)                              |
| Radiation Therapy       | 5/34 (14.7%)                               |

*AJCC: American Joint Commission on Cancer*

**Table 2:** $[^{18}F]FDG$ PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) at PET1, PET2 and their changes.
| PET Parameters | Minimum | Percentile 25 | Median | Percentile 75 | Maximum |
|----------------|---------|---------------|--------|---------------|---------|
| **SUVmax**     |         |               |        |               |         |
| PET1           | 1.8     | 5.3           | 7.9    | 10.6          | 25.1    |
| PET2           | 0.0     | 2.2           | 3.1    | 4.0           | 15.4    |
| ΔPET           | -100%   | -68%          | -58%   | -29%          | +62%    |
| **SUVmean**    |         |               |        |               |         |
| PET1           | 0.7     | 3.0           | 3.8    | 4.9           | 7.0     |
| PET2           | 0.0     | 1.4           | 2.0    | 2.7           | 6.3     |
| ΔPET           | -100%   | -60%          | -46%   | -18%          | +61%    |
| **SUVpeak**    |         |               |        |               |         |
| PET1           | 0.9     | 4.0           | 6.0    | 7.4           | 21.6    |
| PET2           | 0.0     | 1.8           | 2.4    | 3.4           | 10.3    |
| ΔPET           | -100%   | -71%          | -57%   | -25%          | +61%    |
| **MTV**        |         |               |        |               |         |
| PET1           | 5.7     | 85.2          | 161.0  | 262.4         | 1579.9  |
| PET2           | 2.6     | 34.8          | 72.0   | 131.8         | 932.3   |
| ΔPET           | -94%    | -74%          | -44%   | -30%          | +129%   |
| **TLG**        |         |               |        |               |         |
| PET1           | 4       | 54.8          | 104.7  | 259.9         | 1817.3  |
| PET2           | 1.8     | 19.4          | 45.4   | 105.5         | 626.1   |
| ΔPET           | -98%    | -76%          | -58%   | -37%          | +757%   |

**Table 3:** [18F]FDG PET parameters and TTP.
Univariate analysis of PET1, PET2 and ΔPET for TTP in the full study population (bone + soft tissue sarcoma)
| Parameter   | HR   | 95.0% CI Lower | 95.0% CI Upper | P value |
|------------|------|----------------|----------------|---------|
| PET1-SUVmax | 1.10 | 0.99           | 1.22           | 0.061   |
| PET1-SUVmean | 1.15 | 0.86           | 1.53           | 0.346   |
| PET1-SUVpeak | 1.12 | 0.99           | 1.25           | 0.066   |
| PET1-MTV    | 1.00 | 0.99           | 1.00           | 0.810   |
| PET1-TLG    | 1.00 | 0.99           | 1.00           | 0.460   |
| PET2-SUVmax | 1.30 | 1.12           | 1.51           | 0.001   |
| PET2-SUVmean | 1.76 | 1.26           | 1.46           | 0.001   |
| PET2-SUVpeak | 1.38 | 1.14           | 1.66           | 0.001   |
| PET2-MTV    | 1.00 | 1.00           | 1.01           | 0.020   |
| PET2-TLG    | 1.00 | 1.00           | 1.01           | 0.019   |
| ΔSUVmax     | 1.01 | 0.99           | 1.02           | 0.131   |
| ΔSUVmean    | 1.01 | 0.99           | 1.02           | 0.123   |
| ΔSUVpeak    | 1.01 | 0.99           | 1.02           | 0.108   |
| ΔMTV        | 1.01 | 0.99           | 1.02           | 0.146   |
| ΔTLG        | 1.00 | 1.00           | 1.01           | 0.127   |

**Table 4: [18F]FDG PET parameters and response to neoadjuvant CTX.**

ΔMTV parameter was significantly associated with pathological response to Neo-CTX (Mann-Whitney test). *IQR: Interquartile range.*
| Tissue Response to Neo-CTX ≤ 90 % | Tissue Response to Neo-CTX > 90 % | p-value |
|-------------------------------|-------------------------------|---------|
| IQR 25 | Median | IQR 75 | IQR 25 | Median | IQR 75 |         |
| 1-SUVmax | 6.0 | 8.4 | 10.6 | 5.1 | 7.9 | 11.2 | p=0.949 |
| 1-SUVmean | 2.4 | 4.0 | 4.8 | 2.9 | 4.5 | 5.1 | p=0.652 |
| 1-SUVpeak | 3.8 | 6.7 | 7.5 | 4.0 | 5.5 | 6.9 | p=0.813 |
| 1-MTV | 41.1 | 171.4 | 261.3 | 102.7 | 139.5 | 336.7 | p=0.377 |
| 1-TLG | 15.9 | 108.1 | 259.9 | 72.0 | 112.4 | 302.0 | p=0.377 |
| 2-SUVmax | 2.7 | 3.4 | 5.2 | 2.2 | 2.9 | 3.4 | p=0.201 |
| 2-SUVmean | 1.8 | 2.1 | 3.0 | 1.4 | 1.8 | 2.2 | p=0.146 |
| 2-SUVpeak | 2.3 | 2.8 | 4.5 | 1.8 | 1.9 | 2.9 | p=0.146 |
| 2-MTV | 54.7 | 101.7 | 176.1 | 34.8 | 67.2 | 103.4 | p=0.310 |
| 2-TLG | 31.7 | 44.3 | 172.1 | 19.4 | 46.1 | 80.6 | p=0.683 |
| UVmax | -64% | -57% | -11% | -85% | -59% | -36% | p=0.377 |
| UVmean | -51% | -34% | -3% | -69% | -50% | -38% | p=0.102 |
| UVpeak | -62% | -46% | -11% | -74% | -58% | -40% | p=0.234 |
| MTV | -52% | -34% | -14% | -87% | -59% | -35% | p=0.037 |
| LG | -60% | -50% | -22% | -94% | -63% | -45% | p=0.051 |

**Figures**
Figure 1

Study Flowchart.

Treatment schema for patients with Osteosarcoma

| Intervention | 1 D | 1 D | 1 | 1 |
|--------------|-----|-----|---|---|
| Week         | 1   | 2   | 3 | 4 |

| Surgery     | A P | M | A P | M | M | A | M | A | M | M |
|-------------|-----|---|-----|---|---|---|---|---|---|---|
| Week 12     | 13  | 14| 15  | 16| 17| 18| 19| 20| 21| 22|
| Week 13     | 13  | 14| 15  | 16| 17| 18| 19| 20| 21| 22|
| Week 14     | 13  | 14| 15  | 16| 17| 18| 19| 20| 21| 22|

- A: Docetaxel 37.5 mg/m²/day once daily on days 1-2
- P: Cisplatin 60 mg/m²/day once daily on days 1, 2
- M: Methotrexate 12 mg/m²/day once
- I: Ifosfamide 2.5 g/m²/day once daily on days 1-3
- E: Etoposide 100 mg/m²/day once daily on days 1-3

Treatment schema for patients with Synovial Sarcoma and Embryonal Sarcoma of the Liver

| Intervention | 1 D | 1 D | I D | D |
|--------------|-----|-----|-----|---|
| Week         | 1   | 2   | 3   | 4 |

| Surgery     | 1 D | I D |
|-------------|-----|-----|
| Week 13     | 14  | 15  |
| Week 14     | 15  | 16  |
| Week 15     | 16  | 17  |
| Week 16     | 17  | 18  |

- I: Ifosfamide 3 g/m²/dose once daily on days 1-3 for pt ≥ 1 yr (OR 1.5 g/m²/dose for pt < 1 yr)
- D: Docetaxel 37.5 mg/m²/dose once daily on days 1-2 for pt ≥ 1 yr (OR 18.75 mg/m²/dose for pt < 1 yr)
- *Additional radiation given at week 16 in select patients depending on resection status
- + Week 19 docetaxel moved to week 25 if needed in patients receiving post-operative radiation

Figure 2
Figure 3

Overview of primary bone and soft tissue sarcoma localizations and metastatic sites.
Eleven-year-old girl diagnosed with left distal femur osteosarcoma. PET-1 (A,B,C,D) showed stage IIA localized [18F]FDG avid disease (SUVmax 15.2; MTV 113.2 mm3; TLG 84.4). Non sarcoma related [18F]FDG uptake was visualized in the thymus (physiologic), the right adnexa (physiologic) and the right piriformis muscle (functional or strain). PET-2 (E,F,G,H) showed decreased [18F]FDG uptake (SUVmax 2.2; MTV 83.9 mm3; 46.1) after neo-CTX. Diffuse [18F]FDG uptake in bone marrow (H), was related to rebound post-CTX. Patient underwent surgery (necrosis >99%) and had no evidence of disease (NED) at last follow-up. PET1, A: PET 3D MIP; B: Fused PET/CT axial view; C: Fused PET/CT sagittal view; D: CT sagittal view. PET2, E: Fused PET/CT axial view; F: Fused PET/CT sagittal view; G: CT sagittal view; H: PET 3D MIP.
Figure 5

Eighteen-year-old boy diagnosed with osteosarcoma. PET-1 (A,B) showed [18F]FDG -avid lesion in the right proximal fibula (SUVmax 6.6; MTV 102.2 mm3; TLG 91). PET-2 (C,D) did not show major [18F]FDG uptake changes after neo-CTX (SUVmax 8.6; MTV: 67.2; TLG: 80.6). Patient underwent surgery (proximal fibular and mass resection) and viable tumor was seen in the resected specimen. After completion of adjuvant CTX patient developed lung metastatic disease. Patient was alive with disease at last follow up. PET1, A: PET 3D MIP; B: CT axial view; C: Fused PET/CT axial view; D: Fused PET/CT sagittal view. PET2, E: CT axial view; F: Fused PET/CT axial view; G: Fused PET/CT sagittal view; H: PET 3D MIP.
Figure 6

Early interim PET2-SUVmax Kaplan-Meier plot analysis of PET2-SUVmax with TTP (p=0.016). Patients were stratified by the median SUVmax =3.1.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalTables.docx